Comparable immunogenicity of new modality biotherapeutics delivered subcutaneously or intravenously in non-human primates
Unwanted immunogenicity of therapeutic proteins arises through the combination of many factors, with the route of administration considered a significant contributor. Contrary to historic data on vaccine delivery, analysis of various therapeutic protein products indicates that the subcutaneous route...
Saved in:
| Main Authors: | Victoria Koch, Martin Lechmann, Katharine Bray-French, Matthias Füth, Elisabeth Husar, Niels Janssen, Anneliese Schneider, Kay Stubenrauch, Timothy Hickling, Sven Kronenberg |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Journal of Immunotoxicology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/1547691X.2025.2537408 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Immunogenicity risk assessment for tailored mitigation and monitoring of biotherapeutics during development: recommendations from the European Immunogenicity Platform
by: Joanna Grudzinska-Goebel, et al.
Published: (2025-05-01) -
Immune regulatory adjuvant approach to mitigate subcutaneous immunogenicity of monoclonal antibodies
by: Nicole L. Jarvi, et al.
Published: (2024-12-01) -
Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC
by: Federico Cappuzzo, MD, et al.
Published: (2025-05-01) -
The effect of subcutaneous immunoglobulin replacement therapy on serum IgG levels in patients with primary immunodeficiency
by: Selime Özen Bölük, et al.
Published: (2023-06-01) -
Advantage of the subcutaneous immunoglobulin replacement therapy in primary immunodeficient patients with or without secondary protein loss
by: Pınar Gür-Çetinkaya, et al.
Published: (2018-06-01)